Incorporating Biologic Factors Into Breast Cancer Staging

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.

The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.